DKSH has signed a strategic agreement with NanoFCM to promote their NanoAnalyzer range of analytical instruments in key Asian markets. This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market.

Switzerland, February 1, 2021 – DKSH Business Unit Technology has entered into an exclusive partnership with NanoFCM, an innovative manufacturer of a nano flow cytometer platform, headquartered in Fujian, China. DKSH will provide marketing, sales, distribution and after-sales services support in selected markets across Asia, including Singapore, Taiwan and Thailand.

NanoFCM has developed the NanoAnalyzer that now enables true flow-cytometry measurement at the sub-micron scale, and down to particle sizes unreachable by any other flow cytometers. Flow NanoAnalyzer is a powerful tool for life sciences, nanoscience and nanotechnology studies. It can be used for the biomolecular characterization of extracellular vesicles, viruses, nanomedicine and nanomaterials.

“DKSH has in-depth knowledge and a broad network of laboratories doing research on biomolecules and nanoparticles. We are convinced that DKSH is the right partner to help us grow in key Asian markets, especially by introducing our new technology to the extracellular vesicle research community for the development of new cancer therapies,” said Dimitri Aubert, VP Sales & Marketing, NanoFCM.

Marco Farina, Senior Director, Business Development, Scientific Instrumentation, commented: “The partnership with NanoFCM helps strengthen our leadership in biomolecular characterization and expand our life sciences footprint. We are confident to grow the market with NanoCFM, leveraging our knowledge through our Center of Excellence, good sales coverage, strong application support and world class after sales services.”